In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Device/Diagnostics Quarterly Deal Statistics, Q1 2012

A look at financing, M&A, and alliance activity January–March 2012

Executive Summary

Medical device companies raised $1.1 billion, a 40% increase over Q4 2011’s $800 million. Two billion-dollar deals in the resuscitation market boosted device acquisition activity to $4.2 billion. Twenty diagnostics financings brought in a collective $302 million, soaring above the previous quarter’s $269 million. There were seven diagnostics M&A deals completed, totaling $589 million – down yet again.


Related Content

Sientra’s “Stand-By” Series C Shows How To Eliminate Late-Stage Risk
Covidien Acquisitions Keeps Buying Spree Alive
Covidien Gains Ventilators Aimed At Emerging Markets Via Newport Deal
Boston Scientific Buys Cameron Health For First Subcutaneous ICD
ConforMIS Gets Personal With $89 Million Round
Larger VC Deals Could Become More Common In Devices
Roche Pounces On Market-Weakened Illumina
Ventana President Mara Aspinall: An Interview With “The Pink Sheet” DAILY
Pfizer Turns To Ventana To Expand Companion Dx Options For Xalkori
The Neurovascular Market Tilts Toward A Tipping Point


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts